<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-5555</issn>
      <issn pub-type="epub">1432-0584</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23053177</article-id>
      <article-id pub-id-type="pmc">3567333</article-id>
      <article-id pub-id-type="publisher-id">1576</article-id>
      <article-id pub-id-type="doi">10.1007/s00277-012-1576-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Au</surname>
            <given-names>Wing-Yan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fong</surname>
            <given-names>Bonnie M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tam</surname>
            <given-names>Sidney</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kwong</surname>
            <given-names>Yok-Lam</given-names>
          </name>
          <address>
            <phone>+852-22555859</phone>
            <fax>+852-29741165</fax>
            <email>ylkwong@hkucc.hku.hk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China </aff>
        <aff id="Aff2"><label/>Department of Clinical Biochemistry, Queen Mary Hospital, Hong Kong, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>9</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>30</day>
        <month>9</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>92</volume>
      <issue>3</issue>
      <fpage>417</fpage>
      <lpage>418</lpage>
      <history>
        <date date-type="received">
          <day>5</day>
          <month>8</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2012</copyright-statement>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2013</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) is a standard medication for relapsed acute promyelocytic leukemia (APL). However, high blood arsenic levels lead to potentially fatal arrhythmias. As<sub>2</sub>O<sub>3</sub> is renal-excreted and considered contraindicated in renal failure.</p>
    <p>A 42-year-old man was referred for treatment of APL in first relapse, presenting with pancytopenia, impaired renal function, and septicemia. He was treated with all-trans retinoic acid (ATRA, 45&#xA0;mg/m<sup>2</sup>/day) and oral As<sub>2</sub>O<sub>3</sub> (10&#xA0;mg/day) [<xref ref-type="bibr" rid="CR1">1</xref>]. Progressive renal function derangement developed, necessitating reduction of oral As<sub>2</sub>O<sub>3</sub> to 5&#xA0;mg/day. On the third day, the leukocyte count increased to 8.9&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, associated with bilateral pulmonary infiltrates. Features were consistent with the APL differentiation syndrome, which with the underlying septicemia led to anuric acute renal failure. ATRA was stopped. Idarubicin (6&#xA0;mg/m<sup>2</sup>/day&#x2009;&#xD7;&#x2009;5), dexamethasone (12&#xA0;mg/day&#x2009;&#xD7;&#x2009;7), and alternate daily hemodialysis were administered. Oral As<sub>2</sub>O<sub>3</sub> at 5&#xA0;mg was given after each hemodialysis and was stopped after 9&#xA0;days. At 4&#xA0;weeks, marrow examination confirmed complete remission. He remained anuric, and hemodialysis was continued. Oral As<sub>2</sub>O<sub>3</sub> was re-commenced at 2&#xA0;mg after each hemodialysis. Two months later, continuous ambulatory peritoneal dialysis (CAPD) was started. A maintenance regimen for APL, comprising oral As<sub>2</sub>O<sub>3</sub> (5&#xA0;mg/day) and ATRA (20&#xA0;mg twice daily) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], given 2&#xA0;weeks every 2&#xA0;months, was administered. At 6-month follow-up, he remained in remission and was negative for the <italic>PML-RARA</italic> fusion gene characteristic of APL. No cardiac arrhythmias were observed at any time.</p>
    <p>Serum elemental arsenic levels were assayed by inductively coupled plasma mass spectrometry [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], on blood samples sent for creatinine measurement. At 4&#xA0;days, there was a sudden increase of arsenic levels, as the cellular and third-space compartments became saturated and anuria prevented arsenic excretion (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). The arsenic level peaked at 4,240&#xA0;nmol/L, outside the therapeutic range of 500&#x2013;2,000&#xA0;nmol/L typical of oral As<sub>2</sub>O<sub>3</sub>. The commencement of hemodialysis and cessation of oral As<sub>2</sub>O<sub>3</sub> resulted in a fall of arsenic levels parallel to those of creatinine. After oral As<sub>2</sub>O<sub>3</sub> was re-commenced, arsenic levels gradually increased to the therapeutic range (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). As arsenic clearance in oral As<sub>2</sub>O<sub>3</sub> therapy during CAPD had been documented previously [<xref ref-type="bibr" rid="CR3">3</xref>], arsenic assays were not performed after peritoneal dialysis was started.<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>a</bold> Blood arsenic levels during the first 3&#xA0;weeks of hemodialysis. A rapid surge of arsenic levels occurred on day 5, in parallel with a rise in creatinine and further renal function deterioration. Oral arsenic trioxide was stopped on day 9, resulting in a gradual fall of arsenic levels after hemodialysis was commenced. Days (sample number): 3 (1&#x2013;4), 4 (5&#x2013;7), 5 (8), 6 (9), 7 (10&#x2013;13), 8 (14&#x2013;16), 9 (17&#x2013;19), 10 (20&#x2013;21), 11 (22), 12 (23), 13 (24), 14 (24&#x2013;26), 15 (28&#x2013;30), 16 (31&#x2013;32), 17 (33&#x2013;34), 18 (35&#x2013;36), 19 (37&#x2013;38), 20 (39), 21 (40), 22 (41), 23 (42), and 24 (43). <bold>b</bold> Blood arsenic levels during the second month of hemodialysis. With the re-commencement of oral arsenic trioxide on day 42, there was a gradual increase of arsenic levels back to the therapeutic range. Arsenic levels also varied in parallel with creatinine levels during hemodialysis and had remained within the therapeutic range</p></caption><graphic xlink:href="277_2012_1576_Fig1_HTML" id="MO1"/></fig></p>
    <p>As<sub>2</sub>O<sub>3</sub> is a key medication for patients with relapsed APL. Intravenous (i.v.) As<sub>2</sub>O<sub>3</sub>, used in most reports, may lead to lethal arrhythmias due to QT prolongation, which is directly proportional to blood arsenic levels [<xref ref-type="bibr" rid="CR5">5</xref>]. Because i.v. As<sub>2</sub>O<sub>3</sub> leads to a rapid surge of blood arsenic levels, arrhythmia related to QT prolongation is an important adverse effect. Oral As<sub>2</sub>O<sub>3</sub> is slowly absorbed and results in lower blood arsenic levels. Its bioavailability, estimated by area-under-the-curve pharmacokinetically, is comparable to that of i.v. As<sub>2</sub>O<sub>3</sub> [<xref ref-type="bibr" rid="CR6">6</xref>]. Hence, oral As<sub>2</sub>O<sub>3</sub> has the same efficacy, but little risk of arrhythmia [<xref ref-type="bibr" rid="CR5">5</xref>]. In one previous report, blood arsenic levels after i.v. As<sub>2</sub>O<sub>3</sub> were measured in an APL patient on hemodialysis [<xref ref-type="bibr" rid="CR7">7</xref>]. The peak level was 6,450&#xA0;nmol/L, a toxic level that led to termination of i.v. As<sub>2</sub>O<sub>3</sub> therapy. It was concluded that i.v. As<sub>2</sub>O<sub>3</sub> was contraindicated in renal failure [<xref ref-type="bibr" rid="CR7">7</xref>]. In our case, the sudden increase in blood arsenic levels was related to an unanticipated acute renal failure. Timely cessation of oral As<sub>2</sub>O<sub>3</sub> and institution of hemodialysis prevented further increases in arsenic levels. Subsequently, with careful dose adjustment and meticulous monitoring, oral As<sub>2</sub>O<sub>3</sub> was safely administered during hemodialysis. The blood arsenic levels were also kept within the therapeutic range. We have also previously demonstrated the safety of oral As<sub>2</sub>O<sub>3</sub> during CAPD. Therefore, patients on renal replacement therapy are still eligible for oral As<sub>2</sub>O<sub>3</sub> treatment.</p>
  </body>
  <back>
    <ack>
      <sec id="d29e419">
        <title>Conflict of interest</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
      <sec id="d29e424">
        <title>Open Access</title>
        <p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Kumana</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Kou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mak</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
          </person-group>
          <article-title>Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>407</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-01-0298</pub-id>
          <pub-id pub-id-type="pmid">12814916</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Chim</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Lie</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
          </person-group>
          <article-title>Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide</article-title>
          <source>Br J Haematol</source>
          <year>2002</year>
          <volume>117</volume>
          <fpage>130</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.2002.03409.x</pub-id>
          <pub-id pub-id-type="pmid">11918543</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Cheung</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Kumana</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide</article-title>
          <source>Arch Intern Med</source>
          <year>2005</year>
          <volume>165</volume>
          <fpage>1067</fpage>
          <lpage>1068</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.165.9.1067</pub-id>
          <pub-id pub-id-type="pmid">15883249</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
          </person-group>
          <article-title>Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>112</volume>
          <fpage>3587</fpage>
          <lpage>3590</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-06-161000</pub-id>
          <pub-id pub-id-type="pmid">18703707</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siu</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Yung</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kumana</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Tse</surname>
              <given-names>HF</given-names>
            </name>
          </person-group>
          <article-title>Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <fpage>103</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-01-0054</pub-id>
          <pub-id pub-id-type="pmid">16514059</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumana</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Kou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mak</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
          </person-group>
          <article-title>Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies</article-title>
          <source>Eur J Clin Pharmacol</source>
          <year>2002</year>
          <volume>58</volume>
          <fpage>521</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="doi">10.1007/s00228-002-0514-x</pub-id>
          <pub-id pub-id-type="pmid">12451429</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oshimi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugimoto</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia</article-title>
          <source>Acta Haematol</source>
          <year>2009</year>
          <volume>122</volume>
          <fpage>52</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1159/000243724</pub-id>
          <pub-id pub-id-type="pmid">19816009</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
